DLBMX
Price
$19.17
Change
-$0.08 (-0.42%)
Updated
Jul 31 closing price
Net Assets
592.58M
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

DLBMX vs VSCIX

DLBMX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
DLBMX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DLBMX is a Buy and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. DLBMX (593M). VSCIX pays higher dividends than DLBMX: VSCIX (1.23) vs DLBMX (0.15). DLBMX was incepted earlier than VSCIX: DLBMX (28 years) vs VSCIX (29 years). DLBMX (1.15) is less costly to investors than VSCIX (0.03). DLBMX is a more actively managed with annual turnover of: 40.00 vs. VSCIX (17.00). DLBMX has a lower initial minimum investment than VSCIX: DLBMX (1000) vs VSCIX (5000000). VSCIX annual gain was more profitable for investors over the last year : 22.58 vs. DLBMX (13.83). VSCIX return over 5 years is better than : 35.13 vs. DLBMX (5.01).
DLBMXVSCIXDLBMX / VSCIX
Total Expense Ratio1.150.033,833%
Annual Report Gross Expense Ratio1.150.033,833%
Fund Existence28 years29 years-
Gain YTD16.60614.591114%
Front Load6%N/A-
Min. Initial Investment100050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets593M189B0%
Annual Yield % from dividends0.151.2312%
Returns for 1 year13.8322.5861%
Returns for 3 years16.6843.4438%
Returns for 5 years5.0135.1314%
Returns for 10 years45.51156.0729%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C